Key Insights

Highlights

Success Rate

87% trial completion (above average)

Published Results

622 trials with published results (12%)

Research Maturity

2848 completed trials (54% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

7.7%

407 terminated out of 5276 trials

Success Rate

87.5%

+1.0% vs benchmark

Late-Stage Pipeline

13%

665 trials in Phase 3/4

Results Transparency

22%

622 of 2848 completed with results

Key Signals

622 with results87% success407 terminated

Data Visualizations

Phase Distribution

3,129Total
Not Applicable (1131)
Early P 1 (30)
P 1 (447)
P 2 (856)
P 3 (483)
P 4 (182)

Trial Status

Completed2,848
Unknown1,395
Terminated407
Withdrawn279
Recruiting148
Active Not Recruiting133

Trial Success Rate

87.5%

Benchmark: 86.5%

Based on 2848 completed trials

Clinical Trials (5276)

Showing 20 of 20 trials
NCT05728970Completed

POC Performance Evaluation of LumiraDx SARS-CoV-2 Ag Ultra and SARS-CoV-2 & Flu A/B Tests.

NCT07149428Not Yet Recruiting

Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)

NCT04433325CompletedPrimary

COVID-19 Critically Ill Patients' Evolution After Medical Transport by Train From Paris Intensive Care Units to West of France Intensive Care Units

NCT07536308Phase 1RecruitingPrimary

A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults

NCT04557046CompletedPrimary

Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test

NCT04371432CompletedPrimary

Genetics of COVID-19 Susceptibility and Manifestations

NCT04487171Not ApplicableCompleted

Screening for Postpartum Depression and Associated Risk Factors Among Women Who Deliver in Four Hospital in France During the COVID-19 Epidemic

NCT04546737Not ApplicableCompletedPrimary

Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients

NCT04910269Phase 3Suspended

Outpatient Treatment With Anti-Coronavirus Immunoglobulin

NCT03305341Early Phase 1Active Not RecruitingPrimary

Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix

NCT04880109Phase 2TerminatedPrimary

A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.

NCT05935800Active Not Recruiting

The Effect of the COVID-19 Pandemic on Frailty in Liver Transplant Candidates

NCT05920616Not ApplicableCompletedPrimary

Comprehensive Imaging Exam of Convalesced COVID-19 Patients

NCT07298434Phase 3Active Not RecruitingPrimary

Study of VYD2311 for the Prevention of COVID-19

NCT06703034Not ApplicableRecruitingPrimary

Characterization of the IFN-I Response in Subjects Who Experienced Severe or Mild Forms of COVID-19

NCT05074927Not ApplicableCompletedPrimary

Pulmonary Function in Patients Recovering From COVID19 Infection : a Pilot Study

NCT04798053Not ApplicableCompletedPrimary

Impact of COVID-19 Pandemic and Social Distancing on Mental Health of Chronic Inflammatory Rheumatism Affected Patients

NCT04411147Active Not RecruitingPrimary

A Longitudinal Study of COVID-19 Sequelae and Immunity

NCT05369611Enrolling By InvitationPrimary

COVID-19 Experiences in the SELF Cohort

NCT04479358Phase 2TerminatedPrimary

Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19

Scroll to load more

Research Network

Activity Timeline